Article Text

Download PDFPDF

PR076/#172  Cost-effectiveness of maintenance niraparib with an individualized starting dosage compared to routine surveillance in patients with platinum-sensitive recurrent ovarian cancer in China
  1. Yin Shi1,
  2. Di Xiao1,
  3. Shuishi Li2,
  4. Shao Liu1 and
  5. Yu Zhang3
  1. 1Xiangya Hospital, Central South University, Department of Pharmacy, Changsha, China
  2. 2Xiangya Hospital, Central South University, Department of General Surgery, Changsha, China
  3. 3Xiangya Hospital, Central South University, Department of Gynaecology, Changsha, China


Introduction Niraparib maintenance treatment using individualized starting dosage (ISD) demonstrated improved survival outcomes for Chinese platinum-sensitive recurrent ovarian cancer (PSROC) patients versus routine surveillance in NORA trial. We elevated the cost-effectiveness of maintenance niraparib ISD vs routine surveillance in Chinese PSROC patients.

Methods Clinical data from NORA trial was simulated using Markov model for costs and health outcomes. Quality-adjusted life years (QALYs), total costs and incremental cost-effectiveness ratios (ICERs) were measured. One-way and probabilistic sensitivity analysis were performed to estimate the model robustness. Scenario analyses were also conducted. Study period was from June 2022 to January 2023.

Results Niraparib ISD increased QALYs by 0.59 and 0.30 in PSROC patients with and without germline BRCA (gBRCA) mutations, respectively vs routine surveillance; incremental costs were $10,860.79 and $12,098.54, respectively. The ICERs of niraparib ISD over routine surveillance were $18,653.67/QALY and $39,212.99/QALY, respectively. At the willingness-to-pay (WTP) threshold of $37,488/QALY, niraparib ISD enhanced the likelihood of cost-effectiveness from 9.35% to 30.73% in the gBRCA-mutated and from 0.77% to 11.74% in the non-gBRCA mutated patients. In China’s highest per capita GDP region, 74.23% of gBRCA-mutated and 76.10% of non-gBRCA-mutated population considered niraparib to be cost-effective. The probability of maintaining niraparib being cost-effective for those covered by the National Basic Medical Insurance program was 100%.

Conclusion/Implications Maintenance niraparib ISD is cost-effective in gBRCA-mutated PSROC patients vs routine surveillance in China. It is found to be expensive and more effective in non-gBRCA-mutated patients. The optimized niraparib price, economic status, and health insurance coverage may benefit the economic outcome.

Abstract PR076/#172 Figure 1

Tornado diagrams of one-way sensitivity analyses with greatest influence variables. Association of variables with the ICER of niraparib versus routine surveillance for platinum-sensitive recurrent ovarian cancer (A) the gBRCAm cohort (B) the non-gBRCAm cohort. PD, progressed disease

Abstract PR076/#172 Figure 2

Cost-effectiveness acceptability curves generated from the probabilistic sensitivity analysis (10,000 iterations) for the niraparib and routine surveillance groups (A) gBRCAm cohort and (B) Non-gBRCAm cohort

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.